EUVIMEDDescoperă EUVIMED
Open access · CC BY-NC-ND 4.0

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non‐high‐grade serous ovarian carcinomas

Cjh Kramer iD, L Lanjouw, D Ruano, A Ter Elst, G Santandrea, N Solleveld-Westerink, N Werner, A H van der Hout, C D de Kroon, T van Wezel, Lpv Berger, M Jalving and 8 more

The Journal of Pathology · 2024

DOI: 10.1002/path.6218 ↗

At a glance

Journal article in The Journal of Pathology, 2024. Written by Cjh Kramer and 19 co-authors. Institution: Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. Major MEDLINE topics: BRCA1 Protein, Ovarian Neoplasms. Cited 8 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: KWF Kankerbestrijding.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

The identification of causal BRCA1/2 pathogenic variants (PVs) in epithelial ovarian carcinoma (EOC) aids the selection of patients for genetic counselling and treatment decision‐making. Current recommendations therefore stress sequencing of all EOCs, regardless of histotype. Although it is recognised that BRCA1/2 PVs cluster in high‐grade serous ovarian carcinomas (HGSOC), this view is largely unsubstantiated by detailed analysis. Here, we aimed to analyse the results of BRCA1/2 tumour sequencing in a centrally revised, consecutive, prospective series including all EOC histotypes. Sequencing of n = 946 EOCs revealed BRCA1/2 PVs in 125 samples (13%), only eight of which were found in non‐HGSOC histotypes. Specifically, BRCA1/2 PVs were identified in high‐grade endometrioid (3/20; 15%), low‐grade endometrioid (1/40; 2.5%), low‐grade serous (3/67; 4.5%), and clear cell (1/64; 1.6%) EOCs. No PVs were identified in any mucinous ovarian carcinomas tested. By re‐evaluation and using loss of heterozygosity and homologous recombination deficiency analyses, we then assessed: (1) whether the eight ‘anomalous’ cases were potentially histologically misclassified and (2) whether the identified variants were likely causal in carcinogenesis. The first ‘anomalous’ non‐HGSOC with a BRCA1/2 PV proved to be a misdiagnosed HGSOC. Next, germline BRCA2 variants, found in two p53‐abnormal high‐grade endometrioid tumours, showed substantial evidence supporting causality. One additional, likely causal variant, found in a p53‐wildtype low‐grade serous ovarian carcinoma, was of somatic origin. The remaining cases showed retention of the BRCA1/2 wildtype allele, suggestive of non‐causal secondary passenger variants. We conclude that likely causal BRCA1/2 variants are present in high‐grade endometrioid tumours but are absent from the other EOC histotypes tested. Although the findings require validation, these results seem to justify a transition from universal to histotype‐directed sequencing. Furthermore, in‐depth functional analysis of tumours harbouring BRCA1/2 variants combined with detailed revision of cancer histotypes can serve as a model in other BRCA1/2 ‐related cancers. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

BRCA1 ProteinOvarian NeoplasmsFemaleHumansBRCA2 ProteinTumor Suppressor Protein p53Carcinoma, Ovarian Epithelial

Author keywords

BRCA1/2carcinogenesisepithelial ovarian carcinomahomologous recombination deficiencypathogenic variantssequencing

Substances

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 ProteinTumor Suppressor Protein p53

Authors and institutions

  • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

ORCID profiles: Cjh Kramer, T Bosse

Funding

  • KWF Kankerbestrijding

Cite

APA

Kramer, C., Lanjouw, L., Ruano, D., Ter Elst, A., Santandrea, G., Solleveld-Westerink, N., Werner, N., van der Hout, A. H., de Kroon, C. D., van Wezel, T., Berger, L., Jalving, M., Wesseling, J., Smit, V., de Bock, G. H., van Asperen, C. J., Mourits, M., Vreeswijk, M., Bart, J., & Bosse, T. (2024). Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non‐high‐grade serous ovarian carcinomas. The Journal of Pathology. https://doi.org/10.1002/path.6218

Vancouver

Kramer C, Lanjouw L, Ruano D, Ter Elst A, Santandrea G, Solleveld-Westerink N, et al. Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non‐high‐grade serous ovarian carcinomas. The Journal of Pathology. 2024. doi:10.1002/path.6218

BibTeX
@article{Kramer2024,
  author = {Kramer, Cjh and Lanjouw, L and Ruano, D and Ter Elst, A and Santandrea, G and Solleveld-Westerink, N and Werner, N and van der Hout, A H and de Kroon, C D and van Wezel, T and Berger, Lpv and Jalving, M and Wesseling, J and Smit, Vthbm and de Bock, G H and van Asperen, C J and Mourits, Mje and Vreeswijk, Mpg and Bart, J and Bosse, T},
  title = {Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non‐high‐grade serous ovarian carcinomas},
  journal = {The Journal of Pathology},
  year = {2024},
  doi = {10.1002/path.6218}
}
Start for free →